GleamWall
中文EN

BKAIF BioKey (Cayman), Inc.

Pharmaceutical Preparations · OTC · SEC CIK 2108359 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA—
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets468.5%
Debt / equity—
Current ratio0.00x
Interest coverage—

Cash quality & payout

Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302025Q32025-09-302025Q22025-06-30
Income statement
Revenue————
SG&A expense$391,175$250,154$234,033$127,109
Operating income-$391,175-$250,154-$234,033-$127,109
Interest expense$43,705$42,270$40,770$36,264
Pretax income-$397,578-$268,417-$239,758-$145,444
Net income-$397,578-$268,417-$239,758-$145,444
EBITDA-$386,651-$245,522-$228,738-$120,803
EPS (basic)-0.01-0.01-0.01-0.01
EPS (diluted)-0.01-0.01-0.01-0.01
Weighted avg. shares (diluted)30.00M30.00M30.00M30.00M
Balance sheet
Cash & equivalents$110$4,618$52,781$16,466
Current assets$27,435$59,163——
PP&E, net$66,068$70,592——
Total assets$1.61M$1.72M——
Current liabilities$6.31M$5.96M——
Total liabilities$7.56M$7.27M——
Shareholders' equity-$5.95M-$5.55M-$4.87M-$4.63M
Shares outstanding30.00M30.00M——
Cash flow statement
Operating cash flow-$194,508—-$173,867—
Financing cash flow$190,000—$210,182—
Depreciation & amortization$4,524$4,632$5,295$6,306

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.